Skip to main
TNYA

Tenaya Therapeutic (TNYA) Stock Forecast & Price Target

Tenaya Therapeutic (TNYA) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Tenaya Therapeutics Inc is advancing its focus on heart disease through innovative therapies, with particular emphasis on improving clinical outcomes in its gene therapy candidates, TN-201 and TN-401, where the projected chances of success have recently increased, suggesting potential for significant breakthroughs. The company is actively preparing for pivotal trial regulatory alignment and endpoints, highlighting a strategic approach to clinical development that may enhance its market position in the biotechnology sector. Importantly, encouraging preclinical and clinical safety data, alongside clinically meaningful improvements in patient outcomes, reinforces the positive outlook for Tenaya Therapeutics's stock and its future growth.

Bears say

Tenaya Therapeutics Inc faces significant risks associated with potential delays in transitioning its preclinical assets to clinical trials, which could negatively impact market sentiment and lead to downward revisions in financial estimates. Additionally, the emergence of safety signals, particularly related to immune reactions during clinical development, poses a threat to the company's prospects. Furthermore, if Tenaya does not develop adequate manufacturing capacity, it may result in substantial constraints on projected forecasts, further compounding the company's financial outlook challenges.

Tenaya Therapeutic (TNYA) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tenaya Therapeutic and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tenaya Therapeutic (TNYA) Forecast

Analysts have given Tenaya Therapeutic (TNYA) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Tenaya Therapeutic (TNYA) has a Strong Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tenaya Therapeutic (TNYA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.